Auriga Laboratories Appoints Steven D. Gallopo As Vice President of Business Development.

LOS ANGELES -- Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company with products for the treatment of Xerostomia, dermatological conditions, and acute respiratory diseases, announced today that it has appointed Steven D. Gallopo as its Vice President of Business Development. Mr. Gallopo is an accomplished pharmaceutical executive, who has 18 years of experience in marketing, product development, life-cycle management, strategic planning and in national accounts.

Mr. Gallopo joins Auriga from privately-held Stiefel Laboratories Inc., where he was Director of Marketing and managed the acne/rosacea brand team. He joined the company in 2004 and while there, helped establish Duac(R) Topical Gel as the fastest growing acne brand in the US (all specialties) with 12-month TRx volume exceeding 1.2 million1 and annual sales estimated around $125 million. He also led the development of the Brevoxyl Creamy Wash(R), which became the #1 prescription benzoyl peroxide acne wash1, as well as life-cycle management of the brand, which led to the launch of Brevoxyl Acne Wash Kit. He was a strategic member of the New Products Committee and Futures Core Team

Prior to joining Stiefel, he was Senior Marketing Manager from 2002 until 2003 at First Horizon Pharmaceutical Corporation, a leading specialty pharmaceutical company, where he managed the $40 million Sular(R) product line, including the relaunch of the product. He also was a Group Account Director at Adair Green Healthcare Communications, a leading healthcare advertising agency, where he managed high-profile, multi-million dollar cardiovascular, ophthalmic and medical device accounts. Previously, he was Director, Pharmacy Business for Cholestech Corporation, where he established and marketed a diagnostic product line to the domestic pharmacy market.

"I am pleased that we were able to attract such an accomplished executive as Steven to our management team," said Philip S. Pesin, Auriga's founder, chairman and CEO. "His experience in building a highly successful dermatological franchise at Stiefel Laboratories should be invaluable in helping us launch our new line of dermatological products. We will continue to selectively hire additional accomplished pharmaceutical executives to support our strong growth in 2007 and beyond."

Mr. Gallopo holds a Bachelor of Science Degree in Business Administration from Villanova University.

1. IMS MAT Dec 2006

About Auriga Laboratories(TM)

Auriga Laboratories is a specialty pharmaceutical company building an industry changing commission based-sales model. The company's high-growth business model combines driving revenues through a variable cost commission-based sales structure, acquisition of proven brand names, introduction of new brands, and a strategic development pipeline, all of which is designed to enhance its growing direct relationships with physicians nationwide. Auriga's exclusive prescription and over-the-counter product portfolio includes Aquoral(TM) for the treatment of Xerostomia, Akurza(TM) and Xyralid(TM) dermatology products, and the Zinx(TM), Extendryl[R], and Levall[R] families of products for relief of symptoms associated with a range of acute respiratory diseases. For more information, visit: www.aurigalabs.com.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to the company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to its operations, results of operations, growth strategy and liquidity. The company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the company's ability to increase its sales force and the success of such sales force in selling its products in light of competitive and other factors, the regulatory status and/or regulatory compliance of its products, the company's ability to secure additional financing, its ability to sustain market acceptance for its products, its dependence on collaborators, the company's ability to find and execute strategic transactions, its potential exposure to litigation, the company's exposure to product liability claims, and the company's prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.